Tianmu controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2020
CSRC opens investigation into Tianmu Pharmaceutical
Investigation
Tianmu Pharmaceutical said it received an investigation notice from the China Securities Regulatory Commission on April 21, 2020. The regulator decided to open an investigation into the company over suspected violations involving information disclosure. The article also reports allegations concerning undisclosed related-party guarantees and loans. The notice and the reported allegations are described as stated in the source; no further details on the investigation's scope or outcome are provided.
Tianmu Pharmaceutical said it received a China Securities Regulatory Commission investigation notice on April 21. The regulator decided to investigate the company over suspected violations involving information disclosure. The article also reports allegations concerning undisclosed related-party guarantees and loans.
Source excerpt
在2017年至2019年期间，长城集团通过违规占款和连带责任担保等方式，将天目药业卷入数起借贷纠纷案件。而这些借款和担保事项不仅未经过公司董事会审议，亦在之前皆未向外披露。从而导致天目药业多期财务报告信息披露存在重大遗漏。
天目药业公告称，公司于4月21日收到《中国证券监督管理委员会调查通知书》，因公司涉嫌信息披露违法违规，证监会决定对公司进行立案调查。